Welcome to our dedicated page for Ikena Oncology news (Ticker: IKNA), a resource for investors and traders seeking the latest updates and insights on Ikena Oncology stock.
Ikena Oncology, Inc. developed oncology therapies targeting cancer growth, spread, and therapeutic resistance. Company news has centered on its clinical-stage programs, including IK-595, a MEK-RAF molecular glue for RAS and RAF mutant cancers, and IK-930, a TEAD1-selective Hippo pathway inhibitor that the company discontinued.
Recurring updates also cover operating and financial results, research and development spending, restructuring costs, material agreements, shareholder voting matters, capital-structure disclosures, governance actions, and corporate-status developments connected to the former IKNA public company.
Ikena Oncology (Nasdaq: IKNA) will participate in the William Blair Biotech Focus Conference on July 15, 2021. CEO Dr. Mark Manfredi will engage in a panel discussion focused on next-generation approaches to targeted oncology. The panel is scheduled for 9:00 – 9:45 a.m. ET and will be available via a live webcast. Ikena is known for developing therapies targeting cancer's key signaling pathways and has ongoing programs including IK-930 and IK-175. The webcast will be archived for 30 days after the event.
Ikena Oncology (Nasdaq: IKNA) will participate in a fireside chat at the 2021 Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:00 p.m. ET. The event will be available through a live webcast on the company's website, with an archive accessible for 30 days post-event. Ikena is focused on cancer therapies targeting key signaling pathways and has five active programs, including collaborations with Bristol-Myers Squibb for IK-175 and IK-412. For more details, visit www.ikenaoncology.com.
Ikena Oncology (Nasdaq: IKNA) reported its financial results for Q1 2021, marking significant milestones including a successful IPO that raised $143.8 million. The company is focused on developing targeted cancer therapies and has made progress with its clinical pipeline. IND-enabling studies for lead program IK-930 are ongoing, with a submission expected in H2 2021. As of March 31, 2021, Ikena had $281 million in cash, with a net loss of $9.7 million for the quarter, driven by increased R&D expenses.
Ikena Oncology, Inc. (Nasdaq: IKNA) has appointed Maria Koehler, M.D., Ph.D., to its Board of Directors. Dr. Koehler has over 20 years of experience in oncology drug development, previously holding senior positions at Pfizer and leading the development of Ibrance®. Mark Manfredi, CEO of Ikena, expressed enthusiasm for her addition during the company's growth phase, especially as it advances its lead candidate IK-930 into clinical development. Dr. Koehler aims to leverage her extensive experience to drive Ikena's innovative drug candidates forward.
Ikena Oncology, Inc. (Nasdaq: IKNA) announced the closure of its initial public offering (IPO) on 8,984,375 shares of common stock at a price of $16.00 per share, raising approximately $143.8 million in gross proceeds. The offering included the full exercise of the underwriters' option for an additional 1,171,875 shares. Jefferies, Cowen, Credit Suisse, and William Blair served as joint book-running managers. Ikena focuses on cancer therapies targeting critical signaling pathways and has five development programs, including collaborations with Bristol-Myers Squibb.
Ikena Oncology announced the pricing of its initial public offering (IPO), offering 7,812,500 shares at $16.00 each, aimed to raise gross proceeds of $125.0 million. The shares will trade on the Nasdaq starting March 26, 2021, under the ticker symbol IKNA, with the offering expected to close on March 30, 2021. A 30-day option has been granted to underwriters for an additional 1,171,875 shares. Ikena focuses on developing cancer therapies targeting key signaling pathways, and has five programs in development, including collaborations with Bristol-Myers Squibb.